Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3406]

KRdc as induction therapy shows improved OS for NDMM patients

Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK

KRdc as induction therapy shows improved OS for NDMM patients ( Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK )

Epcoritamab monotherapy is well tolerated and efficacious in patients with r/r...

Dr Alexey Danilov - City of Hope National Medical Center, Los Angeles, USA

Epcoritamab monotherapy is well tolerated and efficacious in patients with r/r CLL ( Dr Alexey Danilov - City of Hope National Medical Center, Los Angeles, USA )

Targeted therapies associated with increased risk for and incidence of...

Dr James Martin - Cleveland Clinic, Cleveland, USA

Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer ( Dr James Martin - Cleveland Clinic, Cleveland, USA )

Patients with early-stage, HR+/HER2-negative BC may benefit from adjuvant T-AC...

Dr Nan Chen - The University of Chicago, Chicago, USA

Patients with early-stage, HR+/HER2-negative BC may benefit from adjuvant T-AC therapy more than from TC ( Dr Nan Chen - The University of Chicago, Chicago, USA )

Postmastectomy radiotherapy in 'intermediate-risk' breast cancer does not...

Prof Ian Kunkler - University of Edinburgh, Edinburgh, UK

Postmastectomy radiotherapy in 'intermediate-risk' breast cancer does not impact overall survival ( Prof Ian Kunkler - University of Edinburgh, Edinburgh, UK )

HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in...

Dr Mafalda Oliveira - Vall d'Hebron University Hospital and Vall d'Hebron...

HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC ( Dr Mafalda Oliveira - Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Nivolumab and ipilimumab shows a significantly higher OS rate in nccRCC...

Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany

Nivolumab and ipilimumab shows a significantly higher OS rate in nccRCC compared to standard of care ( Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany )

Pembrolizumab shows improvement in overall survival for clear cell renal cell...

Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany

Pembrolizumab shows improvement in overall survival for clear cell renal cell carcinoma ( Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany )

Irradiation plus ADT with GnRH antagonist vs. GnRH agonist shows similar...

Dr Thomas Zilli - Oncology Institute of Southern Switzerland, Bellinzona...

Irradiation plus ADT with GnRH antagonist vs. GnRH agonist shows similar efficacy in high risk locally advanced PC ( Dr Thomas Zilli - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland )

Study shows association between tumour KIM-1 gene (HAVCR1) expression and...

Dr Panagiotis Vlachostergios - IASO Thessalias General Hospital, Larissa, Greece

Study shows association between tumour KIM-1 gene (HAVCR1) expression and immune infiltrates in RCC ( Dr Panagiotis Vlachostergios - IASO Thessalias General Hospital, Larissa, Greece )

Guiding metastasis-directed therapy with different PET/CT radiotracers affects...

Dr Francesco Lanfranchi - University of Genoa, Genoa, Italy

Guiding metastasis-directed therapy with different PET/CT radiotracers affects distant disease control in HSPC patients ( Dr Francesco Lanfranchi - University of Genoa, Genoa, Italy )

Bladder cancer updates from the second half of 2024

Prof Alison Birtle, Dr Ignacio Durán and Dr Félix Guerrero-Ramos

Bladder cancer updates from the second half of 2024 ( Prof Alison Birtle, Dr Ignacio Durán and Dr Félix Guerrero-Ramos )

More from ecancer